{"response":{"docs":[{"system_create_dtsi":"2026-09-24T18:00:20Z","system_modified_dtsi":"2026-09-24T19:06:57Z","has_model_ssim":["Collection"],"id":"12579v11w","accessControl_ssim":["c41ee0c0-e9e7-483c-824e-aec83b42549b"],"depositor_ssim":["garrejn@ucmail.uc.edu"],"depositor_tesim":["garrejn@ucmail.uc.edu"],"title_tesim":["Non-muscle myosin II 2026"],"collection_type_gid_ssim":["gid://scholar-uc/hyrax-collectiontype/1"],"creator_tesim":["Feroz, Wasim","Garrett, Joan"],"description_tesim":["Background: Non-muscle myosin IIA (NMIIA; encoded by MYH9) has been implicated in breast cancer progression; however, its clinical significance and therapeutic potential in HER2-positive (HER2+) breast cancer remain poorly defined. We investigated the clinical significance of NMIIA and evaluated the anti-tumour activity of the selective NMII inhibitor MT-228.\r\nMethods: NMIIA expression was evaluated by immunohistochemistry in a cohort of 1,142 patients with early-stage invasive breast cancer. Molecular docking and molecular dynamics simulations were performed to characterize binding of MT-228 to NMIIA. The effects of MT-228 were assessed in breast cancer cell lines using assays of cell viability, migration, three-dimensional invasion, DNA damage, apoptosis, and combination studies with FDA approved HER kinase inhibitors Neratinib and Tucatinib. \r\nResults: High NMIIA expression was associated with adverse clinical outcomes in patients with HER2 immunoreactive breast cancer. Computational analyses demonstrated that MT-228 forms favorable binding interactions and stabilized the NMIIA motor domain. MT-228 inhibited cell growth across multiple breast cancer subtypes. In HER2+ cell lines, MT-228 suppressed migration and 3D invasion, increased γH2AX foci formation, caspase-3/7 enzyme activity, and PARP cleavage, and enhanced the anti-proliferative activity of Neratinib and Tucatinib. \r\nConclusions: Our findings identify NMII as a potential therapeutic target in HER2 immunoreactive breast cancer and support further investigation of selective NMII inhibition either alone or in combination with anti-HER therapies. \r\n"],"license_tesim":["http://creativecommons.org/licenses/by/4.0/"],"thumbnail_path_ss":"/assets/collection-a38b932554788aa578debf2319e8c4ba8a7db06b3ba57ecda1391a548a4b6e0a.png","bytes_lts":0,"visibility_ssi":"open","sort_title_ssi":"NONMUSCLE MYOSIN II 2026","read_access_group_ssim":["public"],"edit_access_group_ssim":["admin"],"edit_access_person_ssim":["garrejn@ucmail.uc.edu","ferozwm@mail.uc.edu"],"human_readable_type_tesim":["Collection"],"nesting_collection__pathnames_ssim":["12579v11w"],"nesting_collection__deepest_nested_depth_isi":1,"_version_":1877241305174638592,"timestamp":"2026-09-24T19:06:58.442Z","score":1.0005}],"facets":[{"name":"human_readable_type_sim","items":[{"value":"Collection","hits":1,"label":"Collection"}],"label":"Human Readable Type Sim"},{"name":"creator_sim","items":[{"value":"Feroz, Wasim","hits":1,"label":"Feroz, Wasim"},{"value":"Garrett, Joan","hits":1,"label":"Garrett, Joan"}],"label":"Creator Sim"},{"name":"subject_sim","items":[],"label":"Subject Sim"},{"name":"college_sim","items":[],"label":"College Sim"},{"name":"department_sim","items":[],"label":"Department Sim"},{"name":"language_sim","items":[],"label":"Language Sim"},{"name":"publisher_sim","items":[],"label":"Publisher Sim"},{"name":"date_created_sim","items":[],"label":"Date Created Sim"},{"name":"member_of_collection_ids_ssim","items":[],"label":"Member Of Collection Ids Ssim"},{"name":"generic_type_sim","items":[{"value":"Collection","hits":1,"label":"Collection"}],"label":"Generic Type Sim"}],"pages":{"current_page":1,"next_page":null,"prev_page":null,"total_pages":1,"limit_value":10,"offset_value":0,"total_count":1,"first_page?":true,"last_page?":true}}}